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OBJECTIVES: To determine factors that are responsible for the cost differential
between private and public health facilities through the assessment of the cost per
day of managing six diseases in selected health facilities in Bayelsa State, Nigeria.
METHODS: Prescriptions generated in three tertiary / public hospitals and three
private hospitals for management of Malaria, Typhoid Fever, Essential Hyperten-
sion, Diarrhea, Pneumonia, and Rheumatoid Arthritis over a specified period were
evaluated to determine direct cost of drugs. Questionnaires were used to obtain
relevant data on staff wage bills, and utility bills. Data were analyzed to obtain the
cost per day for each diagnosis, number of days pay required to pay for the treat-
ment using the newly approved N18, 000.00 minimum wage by the Federal Gov-
ernment of Nigeria. RESULTS: Public facilities pay much higher wage bill; all facil-
ities rely heavily on alternative power source; public facilities utilized lesser
number of drugs and shorter duration; polypharmacy, co-morbidities, treatment
duration and number of drug prescribed determine cost of treatment; treatment
cost for all six disease conditions was generally higher in the private facilities;
Hypertension was the most costly to treat at a total cost of N20,570 for 30days
requiring 36.28 days pay to afford; malaria was cheapest to treat for N227 requiring
0.4 day pay; the cost of treatment of the selected diseases are high and
unaffordable. CONCLUSIONS: Generally, costs of prescribed drugs were expensive
in the private facilities. The costs of treatment were also generally not affordable
when viewed from the point of globally accepted affordability standard. Therefore
the need to make the cost of drugs cheaper for health care to be more affordable
becomes imperative.
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OBJECTIVES: Patients with rheumatoid arthritis in Taiwan might receive lifelong
reimbursement for biologics from the Bureau of National Health Insurance (BNHI)
if they satisfied required criteria, which might have a significant impact on the
annual budgets of the BNHI. The objective of this study was to analyze and com-
pare the cost-effectiveness among existing reimbursed eleven possible combina-
tions of biological treatment strategies, while under limited and lifelong treatment
duration assumptions. METHODS: Under limited and lifelong treatment duration
assumptions, Monte-Carlo simulation was used to compare the cost-effectiveness
of eleven possible combinations of biological treatment (Adalimumab, Etanercept,
and Rituximab) strategies in patients with active RA. Treatment duration assump-
tions, effectiveness and utility parameters for different biological treatment strat-
egies were obtained from published papers. Direct medical and drug costs were
estimated according to Taiwan’s National Health Insurance fee schedule for 2011
and the National Health Insurance payment standard. Probability sensitivity anal-
ysis was applied after Monte-Carlo simulation. Incremental costs per quality-ad-
justed life-year (QALY) between the strategies were calculated. Both cost and ef-
fectiveness were discounted at the rate of 3.5%. RESULTS: There were differences
between the results for limited and lifelong treatment duration assumptions. For
limited treatment duration, stratagies with Adalimumab as the first line biologic
(including Adalimumab only; Adalimumab followed by Rituximab; Adalimumab,
Rituximab and Etanercept; Adalimumab, Etanercept and Rituximab; Etanercept,
Adalimumab and Rituximab) were more cost-effective. For lifelong treatment du-
ration, however, strategies with Etanercept as the first line biologic (including Et-
anercept only; Etanercept followed by Rituximab; Etanercept, Rituximab and Ada-
limumab; Etanercept, Adalimumab and Rituximab) were more cost-effective.
CONCLUSIONS: From the Bureau of National Health Insurance point of view, there
seems to be a difference in defining the more cost-effective strategy under the
assumptions, however, the strategy using Etanercept as the first line biologic fol-
lowed by Adalimumab and Rituximab was cost-effective under both assumptions.
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OBJECTIVES: Rheumatoid arthritis (RA) critically impair the quality of life of pa-
tients. Biologic treatments represent a therapeutic alternative for patients who
failed non-biological disease-modifying antirheumatic drugs (DMARDs). Their high
cost, however, is a challenge for clinicians and decision makers. The aim of this
study was to assess the cost-effectiveness of biologic alternatives to treat RA cur-
rently available in China, from a societal perspective.METHODS: A decision anal-
ysis model was developed to simulate the clinical course of patients treated with
Infliximabmethotrexate (MTX), Etanercept, EtanerceptMTX, Adalimumab and
AdalimumabMTXas first-line therapies, aswell as associated costs over one-year
period. Patients were treated for 1-year without discontinuation or switch due to
the lack of efficacy or a major adverse event (AE). Effectiveness measures were
proportion of patients achieving 20%, 50%, 70% improvement following the Amer-
ican College of Rheumatology (ACR20, ACR50 and ACR70) criteria. Costs included
biologics, concomitant drugs, medical follow-up and side effects management.
Clinical response of alternatives and administration costs were extracted from
published literature, while drug costs were collected from National Development
and Reform Commission databases of China. RESULTS: When compared with
InfliximabMTX, Adalimumab and AdalimumabMTX, Etanercept is effective
over other biologic treatments except in ACR70 2% less effectiveness compared
with InfliximabMTX. Etanercept is 56,179US$ less than InfliximabMTX (the
most costly alternative) and 30% more patients meet the ACR20 criteria regarding
Adalimumab (the least effective alternative). When compared with
InfliximabMTX, Adalimumab and AdalimumabMTX, EtanerceptMTX is dom-
inant over other biologic in either ACR20, ACR50 andACR70.CONCLUSIONS:Due to
their lower costs and favorable effectiveness profile, Etanercept or
EtanerceptMTX are both less costly and the most effective over other biologic
treatments in the management of RA in China.
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OBJECTIVES: Denosumab has recently been adopted in the National Health Insur-
ance (NHI) program as a therapy in treating and preventing osteoporosis and the
reimbursed price for denosumab is NT$12,688. It is important to assess if deno-
sumab represents good value of money. The aim of this study was to evaluate the
potential cost-effectiveness of denosumab in the treatment of osteoporosis among
postmonopausal women in Taiwan. METHODS: A Markov cohort model was
adapted to estimate and costs per quality-adjusted life-year (QALY) gained of a
3-year denosumab treatment compared with no treatment and the current treat-
ments, alendronate, ibandronate, raloxifene or zoledronate used in Taiwan. The
model was populated with costs and epidemiological data for Taiwan and the
patients fitted the model were corresponding to the patients in the “Fracture Re-
duction Evaluation of Denosumab in Osteoporosis every 6 Months” (FREEDOM)
trial. One-way and probabilistic sensitivity analyses were conducted to assess pa-
rameter uncertainty. RESULTS: In the base-case analysis, denosumab was shown
to be “cost saving” compared to alendronate, ibandronate, as well as raloxifene.
The results remain robust regardless of whether GI event was presence or the
annual drug cost of denosumab was set higher. In the base-case when denosumab
was compared to zoledronate, the ICER was NT$1,248,366 per QALY gained.
CONCLUSIONS: Based upon currently available data, denosumab is considered
cost-saving compared with alendronate, ibandronate and raloxifene and was
found to be cost-effective when compared with zoledronate.
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OBJECTIVES: In November 2011, Center for Drug Evaluation completed the project
which aimed to re-evaluate the currently reimbursed biologics for rheumatoid
arthritis (RA), and to establish the evidence-based revision rules of reimbursed
items covered by National Health Insurance (NHI). As part of the project, this study
reviewed the cost-effectiveness of reimbursed biologics (etanercept, adalimumab
and rituximab) and other non-reimbursed biologics for adult patients.METHODS:
Electronic databases including PubMed, CEPS (Chinese Electronic Periodical Ser-
vices) and CETD (Chinese Electronic Theses and Dissertation Service) were
searched up to October 2011. A total of 130 articles were reviewed and 37 were
identified. The SIGN 50 instrument was subsequently applied to assess the quality
of evidence. To present the differences among studies, we summarized the cost-
effectiveness of biologics for DMARD-IR (inadequate response to disease-modify-
ing anti-rheumatic drugs) and TNF-IR patients (inadequate response to tumor ne-
crosis factor-alpha inhibitors), respectively. RESULTS: For DMARD-IR patients,
twenty cost-effectiveness analyses (CEAs), most of high quality, were included. In
summary, two reimbursed biologics including etanercept and adalimumab were
considered as cost-effective alternatives in most foreign insurers comparing with
DMARDs. Combination therapies of biologics andmethotrexatewere cost-effective
comparing with monotherapy of biologics. However, the findings were still incon-
sistent when comparing etanercept with adalimumab, For TNF-IR patients, 10
CEAs, most of high quality, were included. Overall, rituximab was considered cost-
effective in most foreign insurers. CONCLUSIONS: Existing studies suggested that
the reimbursed biologicswere cost-effective alternatives inmost foreign countries.
Nevertheless the cost-effectiveness of technologies might vary across countries,
because the health care setting, clinical pattern, characteristics of patients, and
relative prices are difference in nature. A localized decision analytic model is still
needed formore relevant and precise assessment. This review, however, limited by
the research resource, provided only the preliminary evidence to inform the deci-
sion making.
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OBJECTIVES: To assess co-morbidity, quality of life (QOL), work/productivity loss,
and medical resource utilization (MRU) in patients with Ankylosing Spondylitis
(AS) in urban China. METHODS: Patients’ self-reported data were collected from
2010 National Health and Wellness Survey (NHWS). This survey represents urban
population 18 years and older. QOLwasmeasured by the physical component score
(PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of
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